英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
maquina查看　maquina　在百度字典中的解释百度英翻中〔查看〕
maquina查看　maquina　在Google字典中的解释Google英翻中〔查看〕
maquina查看　maquina　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Ibrutinib Resistance Mechanisms and Treatment Strategies for . . .
    BTK is a central contributor to B-cell lymphoma pathogenesis, as it is significantly more active (increased phosphorylation) in B-cell lymphomas than in normal B-cells Additionally, BTK plays a fundamental role in modulating chemokine and integrin signaling (CXCR4), thereby regulating B-cell trafficking and tissue homing [ 7 ]
  • Ibrutinib improves diffuse large B-cell lymphoma survival
    NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
  • Imbruvica (Ibrutinib) | Lymphoma News Today
    A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
  • CLL and SLL Treatment | IMBRUVICA® (ibrutinib)
    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
  • Ibrutinib improves survival for younger people with diffuse . . .
    “This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
  • IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the . . .
    2 Dreyling, et al Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell
  • Official Healthcare Professional Website | IMBRUVICA . . .
    Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA ® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8%, and grade 3 or 4 anemia in 2 8%, based on laboratory measurements Monitor complete blood counts monthly
  • Imbruvica gets positive EMA Committee opinion for untreated . . .
    Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International Written By : Ruchika Sharma | Medically Reviewed By : Dr Kamal Kant Kohli Published On 2025-06-22T17:30:45+05:30 | Updated On 22 Jun 2025 5:31 PM IST
  • Ibrutinib as first-line therapy for mantle cell lymphoma: a . . .
    Advanced stage mantle cell lymphoma (MCL) is an incurable B-cell malignancy with a wide spectrum of clinical presentations and management approaches spanning active surveillance for asymptomatic and clinically indolent disease to urgent immunochemotherapy for aggressive variants 1 Selected fitter patients can achieve long remissions after intensive cytarabine- and rituximab-containing
  • U. S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment . . .
    Marginal zone lymphoma (MZL) is a slow-growing B-cell lymphoma arising from white blood cells (lymphocytes) at the edges of lymphoid tissue 3 MZL accounts for approximately 8% of all cases of non-Hodgkin's lymphoma in adults, and the median age of diagnosis is 65 years old 3,4 There are three sub-types of MZL: mucosa-associated lymphoid
  • Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
    Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
  • Imbruvica oral forms: Side effects, dosage, uses, and more
    Imbruvica for diffuse large B-cell lymphoma Imbruvica isn’t currently approved for use in people with diffuse large B-cell lymphoma (DLBCL) However, your doctor may prescribe the drug off





中文字典-英文字典  2005-2009